Ieq Capital LLC Takes $1.50 Million Position in Agios Pharmaceuticals, Inc. $AGIO

Ieq Capital LLC bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 40,404 shares of the biopharmaceutical company’s stock, valued at approximately $1,499,000. Ieq Capital LLC owned about 0.07% of Agios Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of AGIO. BlackRock Inc. bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $239,582,000. Bellevue Group AG raised its position in Agios Pharmaceuticals by 3.5% during the third quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after acquiring an additional 124,586 shares in the last quarter. State Street Corp grew its position in shares of Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after acquiring an additional 845,433 shares during the period. Erste Asset Management GmbH increased its stake in shares of Agios Pharmaceuticals by 1.4% during the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares during the last quarter.

Analyst Ratings Changes

AGIO has been the topic of a number of recent analyst reports. Truist Financial lowered their price target on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. HC Wainwright lifted their target price on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. lifted their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Citigroup raised their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $41.25.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the sale, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. This trade represents a 35.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $33.99 on Thursday. The stock has a market capitalization of $2.03 billion, a P/E ratio of -4.85 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00. The stock has a fifty day moving average of $35.91 and a 200-day moving average of $31.56.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. On average, research analysts forecast that Agios Pharmaceuticals, Inc. will post -5.8 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.